Pharmacyte Biotech, Inc. (PMCB) SEC Filings — 2025
13 SEC filings for Pharmacyte Biotech, Inc. (PMCB) in 2025.
Filings
- PharmaCyte Swings to $15.8M Loss Amidst Warrant Revaluation, FDA Hold — 10-Q · Dec 18, 2025
- PharmaCyte Biotech Faces Delisting Notice — 8-K · Dec 5, 2025
- PharmaCyte Biotech Files 8-K/A Amendment — 8-K/A · Nov 18, 2025
- PharmaCyte Biotech Reports Director/Officer Changes & Shareholder Votes — 8-K · Oct 31, 2025
- PharmaCyte Seeks Shareholder Nod for Major Dilution, Equity Plan Boost — DEF 14A · Oct 6, 2025
- PharmaCyte Swings to $8.4M Loss Amid FDA Hold, Strategic Review — 10-Q · Sep 15, 2025
- PharmaCyte Biotech Enters Material Agreement, Completes Asset Deal — 8-K · Sep 5, 2025
- PharmaCyte Biotech Files 8-K on Agreements and Equity Sales — 8-K · Aug 18, 2025
- PharmaCyte Biotech Acquires Femasys, Eyes New Growth Avenues — 10-K · Aug 11, 2025
- PharmaCyte Biotech Files 8-K on Security Holder Vote Matters — 8-K · Apr 24, 2025
- PharmaCyte Biotech Files Q3 10-Q — 10-Q · Mar 17, 2025
- PharmaCyte Biotech Files Definitive Proxy Statement — DEF 14A · Mar 10, 2025
- PharmaCyte Biotech Files 8-K: Accountant Change — 8-K · Feb 26, 2025